Literature DB >> 27812250

Proliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma.

Sarah Grace Priyadarshini1, Debdatta Basu1, Rakhee Kar1, T K Dutta1.   

Abstract

Multiple myeloma is a neoplasm of plasma cells characterised by the presence of M protein in serum and urine. Angiogenesis and proliferation play a major role in the pathogenesis of various neoplasms. The study evaluated proliferation and angiogenesis in 48 cases of myeloma, and correlated it with morphological and clinical parameters. The histomorphological features like plasma cell morphology, percentage of plasma cells and pattern of infiltration were studied in the bone marrow aspirate and trephine biopsy. Angiogenesis was assessed by calculating the microvessel density (MVD) using immunohistochemistry for CD34. Proliferation was assessed using Ki67 and CD38 highlighted the plasma cells. The mean Ki67 % was found to be significantly higher (19.6 % range 2-40 %) in poorly differentiated morphology compared to well differentiated morphology (4.06 % range 0.2-20 %) (p = 0.003). The mean MVD in the well differentiated morphology was 10.6 (range 1.2-47.4) compared to 20.3 (range 6.9-39.6) in the poorly differentiated morphology (p = 0.04). The mean MVD was 5.7 (range 1.2-12.8) in the interstitial pattern of infiltration compared to 20.04 (2.9-47.4) in the diffuse pattern (p < 0.0001). The mean MVD was 6.4 in cases with serum albumin >3.5 gm/dl compared to 13.3 in cases with serum albumin <3.5 gm/dl (p = 0.009). Both the Ki67 and MVD showed an increasing trend with the clinical staging. Thus the study of proliferation and angiogenesis in bone marrow biopsy is useful for prognosticating patients with multiple myeloma.

Entities:  

Keywords:  Angiogenesis; Microvessel density; Myeloma; Proliferation

Year:  2016        PMID: 27812250      PMCID: PMC5074966          DOI: 10.1007/s12288-016-0642-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  14 in total

1.  The biological and clinical significance of the KI-67 growth fraction in multiple myeloma.

Authors:  J Drach; C Gattringer; H Glassl; D Drach; H Huber
Journal:  Hematol Oncol       Date:  1992 Mar-Apr       Impact factor: 5.271

2.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  A Vacca; D Ribatti; L Roncali; G Ranieri; G Serio; F Silvestris; F Dammacco
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

3.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

4.  Risk groups of myeloma patients by histologic pattern and proliferative activity.

Authors:  A Pich; L Chiusa; F Marmont; R Navone
Journal:  Am J Surg Pathol       Date:  1997-03       Impact factor: 6.394

5.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Authors:  Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

6.  Prognostic significance of bone marrow histology in multiple myeloma.

Authors:  R Subramanian; D Basu; T K Dutta
Journal:  Indian J Cancer       Date:  2009 Jan-Mar       Impact factor: 1.224

7.  Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade.

Authors:  J L Xu; R Lai; T Kinoshita; N Nakashima; T Nagasaka
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

8.  Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.

Authors:  J Thaler; F Fechner; M Herold; H Huber
Journal:  Leuk Lymphoma       Date:  1994-01

Review 9.  Biology and treatment of multiple myeloma.

Authors:  R Niesvizky; D Siegel; J Michaeli
Journal:  Blood Rev       Date:  1993-03       Impact factor: 8.250

10.  The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Authors:  M G Alexandrakis; F H Passam; C Dambaki; C A Pappa; E N Stathopoulos
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.